Positive top-line results from the pivotal BLUE-C study showed that the next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30% lower false positive rate compared to DeeP-C, the FDA registrational trial for Cologuard.
“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”
